Saturday, October 3, 2026

EUR/CHF Is 1% Down In The Last 10 Sessions

ViaNews Editorial Team

February 17, 2023

EUR/CHF Is 1% Down In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.01% for the last 10 sessions. At 11:07 EST on Friday, 17 February, EUR/CHF (EURCHF) is $0.99.

EUR/CHF's yearly highs and lows, it's 4.932% up from its 52-week low and 5.897% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.29%, a negative 0.09%, and a positive 0.30%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.44% (last week), 0.38% (last month), and 0.30% (last quarter), respectively.

News about

  • Usd/jpy snaps two-day uptrend despite upbeat yields, hawkish fed talks. According to FXStreet on Wednesday, 15 February, "Moving on, a lack of major data/events from Japan puts the USD/JPY pair at the mercy of the US catalysts for clear directions. ", "That said, S&P 500 Futures trace Wall Street's downbeat closing to highlight the mildly offbeat mood and weigh on the USD/JPY prices, mainly due to the Japanese Yen's (JPY) traditional risk-safety allure."
  • Usd/jpy price analysis: bulls flirt with 133.00 inside monthly rising wedge. According to FXStreet on Wednesday, 15 February, "That said, the USD/JPY remains inside a one-month-old rising wedge bearish chart formation.", "Even if the quote rises past 133.60, a two-month-old horizontal resistance region near 134.50-70, will precede the 200-DMA level surrounding 136.90 to challenge the USD/JPY bulls."
  • Usd/jpy price analysis: back above 134.00, as bulls moved in and crushed the 200-dma. According to FXStreet on Wednesday, 15 February, "Even though the RSI shifted overbought, as long as it stays below 80, it portrays the USD/JPY in a strong uptrend. ", "Hence, the USD/JPY shifted bullish during the session, though a daily close above the 200-day EMA would keep bulls hopeful for further upside. "

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com